Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Telomere Attrition and Chromosomal Instability During Long-Term Cultivation of Hematopoietic Stem Cells,

Kathrin Lange, Dipl. Biochem., Beate Kuhlmann, PhD, Andrea Schienke, Axel Schambach, MD PhD, Ute Modlich, DVM, PhD, Christopher Baum, MD, Brigitte Schlegelberger, M.D., Gudrun Göhring, MD

Blood (2011) 118 (21): 4001.

https://doi.org/10.1182/blood.V118.21.4001.4001

Published: 2011

Journal Articles

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Guntram Buesche, M.D., Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2011) 118 (21): 3819.

https://doi.org/10.1182/blood.V118.21.3819.3819

Published: 2011

Journal Articles

ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,

Katharina Wagner, MD, Frederik Damm, MD, Michael A Morgan, PhD, Felicitas Thol, M.D., Haiyang Yun, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Michael Heuser, M.D., Arnold Ganser, MD, Jürgen Krauter, MD

Blood (2011) 118 (21): 3554.

https://doi.org/10.1182/blood.V118.21.3554.3554

Published: 2011

Journal Articles

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

Blood (2011) 118 (21): 3558.

https://doi.org/10.1182/blood.V118.21.3558.3558

Published: 2011

Journal Articles

Evidence for Cooperation of Receptor Tyrosine Kinases and Activating NOTCH Mutations to Hyperactivate mTOR in T-Cell Leukemia: A Rationale Basis for Targeted Therapy

Adrian Schwarzer, MD, Johann Meyer, PhD, Martijn Brugman, PhD, Axel Schambach, MD PhD, Martin Stanulla, MD, MSc, Martin Schrappe, MD, Doris Steinemann, PhD, Brigitte Schlegelberger, M.D., Christopher Baum, MD, Zhixiong Li, MD

Blood (2011) 118 (21): 1381.

https://doi.org/10.1182/blood.V118.21.1381.1381

Published: 2011

Journal Articles

Therapy-Related Myelodysplastic Syndrome Following Treatment for Childhood Acute Lymphoblastic Leukemia: Outcome of Patients Registered in the EWOG-MDS 98/06 Studies,

Brigitte Strahm, MD, Roland Amann, Barbara De Moerloose, M.D., Michael Dworzak, M.D., Henrik Hasle, M.D., Markus Schmugge, M.D., Jan Stary, M.D., Marry M. van den Heuvel-Eibrink, M.D., Marco Zecca, M.D., Brigitte Schlegelberger, M.D., Franco Locatelli, MD, Charlotte M Niemeyer

Blood (2011) 118 (21): 4130.

https://doi.org/10.1182/blood.V118.21.4130.4130

Published: 2011

Journal Articles

Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia

Blood (2011) 118 (21): 2797.

https://doi.org/10.1182/blood.V118.21.2797.2797

Published: 2011

Journal Articles

Telomere Shortening and Chromosomal Instability in Chronic Lymphocytic Leukemia

Gudrun Göhring, MD, Caroline Fedder, Kathrin Lange, Dipl. Biochem., Andrea Schienke, Winfried Hofmann, PhD, Hans H. Kreipe, MD, Brigitte Schlegelberger, M.D.

Blood (2011) 118 (21): 1761.

https://doi.org/10.1182/blood.V118.21.1761.1761

Published: 2011

Journal Articles

Efficacy of Gene Therapy for Wiskott-Aldrich-Syndrome

Blood (2011) 118 (21): 165.

https://doi.org/10.1182/blood.V118.21.165.165

Published: 2011

Journal Articles

Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation

Christian Koenecke, MD, Felicitas Thol, MD, Patrick Löffeld, Stefanie Buchholz, MD, Michael Stadler, MD, Gudrun Göhring, MD, Elke Dammann, Moritz Kleine, MD, Wiebke Brauns, Michael Hallensleben, MD, Jörg Schmidtke, MD, Brigitte Schlegelberger, M.D., Jürgen Krauter, Arnold Ganser, MD, Michael Heuser, M.D.

Blood (2011) 118 (21): 1709.

https://doi.org/10.1182/blood.V118.21.1709.1709

Published: 2011

Journal Articles

In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival.

Frank G Rücker, M.D., Richard F Schlenk, M.D., Lars Bullinger, M.D., Helena Kett, Annegret Becker, Carla-Maria Kugler, Thorsten Zenz, MD, Peter Lichter, Ph.D., Jürgen Krauter, M.D., Brigitte Schlegelberger, M.D., Arnold Ganser, M.D., Hartmut Döhner, M.D., Konstanze Döhner, M.D.

Blood (2009) 114 (22): 2632.

https://doi.org/10.1182/blood.V114.22.2632.2632

Published: 2009

Journal Articles

Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.

Gudrun Göhring, MD, Aristoteles Giagounidis, Guntram Büsche, MD, Hans Kreipe, MD, Martin Zimmermann, PhD, Eva Hellstrom-Lindberg, MD, PhD, Carlo Aul, Brigitte Schlegelberger, M.D.

Blood (2009) 114 (22): 3818.

https://doi.org/10.1182/blood.V114.22.3818.3818

Published: 2009

Journal Articles

Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure.

Aristoteles Giagounidis, Gudrun Göhring, MD, Sabine Haase, Carlo Aul, Brigitte Schlegelberger, M.D., Andrea Kuendgen, Regina Herbst, MD, Gerhard Ehninger, Uwe Platzbecker

Blood (2009) 114 (22): 3807.

https://doi.org/10.1182/blood.V114.22.3807.3807

Published: 2009

Journal Articles

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Pierre Fenaux, Aristotle Giagounidis, Dominik Selleslag, MD, Odile Beyne-Rauzy, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Moshe Mittelman, MD, Petra Muus, MD, PhD, Peter te Boekhorst, MD, PhD, Guillermo Sanz, MD, PhD, Consuelo del Cañizo, Agnes Guerci-Bresler, Brigitte Schlegelberger, M.D., Carlo Aul, Hans Kreipe, MD, Gudrun Goehring, Robert Knight, MD, John Francis, Tommy Fu, Eva Hellstrom-Lindberg, MD, PhD

Blood (2009) 114 (22): 944.

https://doi.org/10.1182/blood.V114.22.944.944

Published: 2009

Journal Articles

Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).

Peter Paschka, M.D., Juan Du, M.D., Richard F. Schlenk, M.D., Verena I. Gaidzik, M.D., Lars Bullinger, M.D., Andrea Corbacioglu, Ph.D., Manuela Zucknick, Ph.D., Axel Benner, M.Sc., Frank Stegelmann, M.D., Daniela Späth, Sabine Kayser, M.D., Brigitte Schlegelberger, M.D., Jürgen Krauter, M.D., Arnold Ganser, M.D., Hartmut Döhner, M.D., Konstanze Döhner, M.D.

Blood (2009) 114 (22): 824.

https://doi.org/10.1182/blood.V114.22.824.824

Published: 2009

Journal Articles

Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup.

Jürgen Krauter, MD, Katharina Wagner, M.D., Irina Schäfer, Rolf Marschalek, Ph.D., Claus Meyer, M.D., Gerhard Heil, M.D., Markus Andreas Schaich, M.D., Gerhard Ehninger, M.D., Dietger W. Niederwieser, M.D., Rainer Krahl, M.D., Thomas Buchner, M.D., Cristina Sauerland, Brigitte Schlegelberger, M.D., Konstanze Dohner, M.D., Hartmut Dohner, M.D., Richard Schlenk, M.D., Arnold Ganser, M.D.

Blood (2007) 110 (11): 759.

https://doi.org/10.1182/blood.V110.11.759.759

Published: 2007

Journal Articles

Inactivation of the Myc−Induced DNA Damage Response Promotes Lymphomagenesis and Treatment Resistance In Vivo.

Maurice Reimann, PhD, Christoph Loddenkemper, M.D., Cornelia Rudolph, Ph.D., Harald Stein, M.D., Brigitte Schlegelberger, M.D., Bernd Dorken, M.D., Clemens A. Schmitt, M.D.

Blood (2006) 108 (11): 774.

https://doi.org/10.1182/blood.V108.11.774.774

Published: 2006

NARROW

Telomere Attrition and Chromosomal Instability During Long-Term Cultivation of Hematopoietic Stem Cells,

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

Evidence for Cooperation of Receptor Tyrosine Kinases and Activating NOTCH Mutations to Hyperactivate mTOR in T-Cell Leukemia: A Rationale Basis for Targeted Therapy

Therapy-Related Myelodysplastic Syndrome Following Treatment for Childhood Acute Lymphoblastic Leukemia: Outcome of Patients Registered in the EWOG-MDS 98/06 Studies,

Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia

Telomere Shortening and Chromosomal Instability in Chronic Lymphocytic Leukemia

Efficacy of Gene Therapy for Wiskott-Aldrich-Syndrome

Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation

In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival.

Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.

Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure.

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).

Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup.

Inactivation of the Myc−Induced DNA Damage Response Promotes Lymphomagenesis and Treatment Resistance In Vivo.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only